English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Purpose: The aim of this study was to find the dose of agonistic 4-1BB monoclonal antibody (㎃b) that results in optimal T cell activation. Methods: Cancer was induced in mice by an intrahepatic parenchymal injection of 1×10? cells of CT26 cells. Cancer-carrying mice (n=84) were divided into seven groups and treated with either rat IgG or agonistic 4-1BB monoclonal antibody (㎃b) (5㎍, 10㎍, 20㎍, 100㎍, 200㎍, or 300㎍). All treatments were administered intraperitoneally on days 7, 9, and 11. Mice from each group were sacrificed on days 14, 28, and 42. Harvested livers were weighed and the numbers of T cells in the splenocytes were analyzed with a FACS Vantage flow cytometer. Results: Liver weights increased when 5㎍ of agonistic 4-1BB ㎃b was administered, but showed no additional weight increase for doses greater than 10㎍. The absolute numbers of CD4 and CD8 T cells increased in groups treated with low doses of agonistic 4-1BB ㎃b (5㎍, 10㎍, or 20㎍), but did not increase in the groups treated with high doses of ㎃b (100㎍, 200㎍, or 300㎍). The levels of CD4/annexin V and CD8/annexin V increased as the dose increased, and the absolute cell numbers of CD4/annexin V were greater than those of CD8/annexin V. Conclusion: Liver weight, including the cancer mass, failed to increase at agonistic 4-1BB ㎃b doses greater than 10㎍. A high dose (≥100㎍) of agonistic 4-1BB ㎃b resulted in lower counts of absolute T cells. This study suggests that a low dose (20㎍) of agonistic 4-1BB ㎃b can be used for optimal T cell activation in combination with other anti-cancer treatments.

Investigation of the Effective Dose of Agonistic 4-1BB Monoclonal Antibody in a Murine Colon Cancer Metastasis Model